Behm-Ansmant I, Rehwinkel J, Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harbor symposia on quantitative biology: Cold Spring Harbor Laboratory Press, 2006. pp. 523-530.

Martinez NJ, Walhout AJ: The interplay between transcription factors and microRNAs in genome‐scale regulatory networks. Bioessays 2009, 31:435-445.

Multilevel regulation of gene expression by microRNAs.

Science. 319: 1789-1790Pedroza-Torres A. Romero-Córdoba S.L. Justo-Garrido M. Salido-Guadarrama I. Rodríguez-Bautista R. Montaño S. Muñiz-Mendoza R. Arriaga-Canon C. Fragoso-Ontiveros V. Álvarez-Gómez R.M.

MicroRNAs in tumor cell metabolism: roles and therapeutic opportunities.

Frontiers in oncology. : 1404Nakamura K. Sawada K. Yoshimura A. Kinose Y. Nakatsuka E. Kimura T.

Clinical relevance of circulating cell-free microRNAs in ovarian cancer.

Molecular cancer. 15: 1-10Schwarzenbach H. Nishida N. Calin G.A. Pantel K.

Clinical relevance of circulating cell-free microRNAs in cancer.

Nature reviews Clinical oncology. 11: 145-156Javidi M.A. Ahmadi A.H. Bakhshinejad B. Nouraee N. Babashah S. Sadeghizadeh M.

Cell-free microRNAs as cancer biomarkers: the odyssey of miRNAs through body fluids.

Medical oncology. 31: 1-11Armand-Labit V. Pradines A.

Circulating cell-free microRNAs as clinical cancer biomarkers.

Biomolecular concepts. 8: 61-81Hooten N.N. Fitzpatrick M. Wood 3rd, W.H. De S. Ejiogu N. Zhang Y. Mattison J.A. Becker K.G. Zonderman A.B. Evans M.K.

Age-related changes in microRNA levels in serum.

Aging (Albany NY). 5: 725Olivieri F. Rippo M.R. Procopio A.D. Fazioli F.

Circulating inflamma-miRs in aging and age-related diseases.

Frontiers in genetics. 4: 121Ozen M. Creighton C. Ozdemir M. Ittmann M.

Widespread deregulation of microRNA expression in human prostate cancer.

Oncogene. 27: 1788-1793Medina-Villaamil V. Martínez-Breijo S. Portela-Pereira P. Quindós-Varela M. Santamarina-Cainzos I. Antón-Aparicio L. Gómez-Veiga F.

Circulating microRNAs in blood of patients with prostate cancer.

Actas Urológicas Españolas (English Edition). 38: 633-639Porkka K.P. Pfeiffer M.J. Waltering K.K. Vessella R.L. Tammela T.L. Visakorpi T.

MicroRNA expression profiling in prostate cancer.

Cancer research. 67: 6130-6135Zhang W. Zang J. Jing X. Sun Z. Yan W. Yang D. Guo F. Shen B.

Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer.

Journal of translational medicine. 12: 1-12Ambs S. Prueitt R.L. Yi M. Hudson R.S. Howe T.M. Petrocca F. Wallace T.A. Liu C.-G. Volinia S. Calin G.A.

Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.

Cancer research. 68: 6162-6170

The interactions of microRNA and epigenetic modifications in prostate cancer.

Cancers. 5: 998-1019

PSA and beyond: alternative prostate cancer biomarkers.

Cellular Oncology. 39: 97-106Selth L. Townley S. Bert A. Stricker P. Sutherland P. Horvath L. Goodall G. Butler L. Tilley W.

Circulating microRNAs predict biochemical recurrence in prostate cancer patients.

British journal of cancer. 109: 641-650Casanova-Salas I. Rubio-Briones J. Fernández-Serra A. López-Guerrero J.A.

miRNAs as biomarkers in prostate cancer.

Clinical and Translational Oncology. 14: 803-811Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA: a cancer journal for clinicians. 68: 394-424

Epidemiology of prostate cancer.

World journal of oncology. 10: 63Rawla P. Sunkara T. Gaduputi V.

Epidemiology of pancreatic cancer: global trends, etiology and risk factors.

World journal of oncology. 10: 10

Bostwick DG, Burke HB, Djakiew D, Euling S, Ho Sm, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ: Human prostate cancer risk factors. Cancer: Interdisciplinary International Journal of the American Cancer Society 2004, 101:2371-2490.

Kash D.P. Lal M. Hashmi A.H. Mubarak M.

Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective.

Asian Pacific Journal of Cancer Prevention. 15: 3087-3091

Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma.

The Journal of the American Board of Family Practice. 16: 95-101Woo S. Suh C.H. Eastham J.A. Zelefsky M.J. Morris M.J. Abida W. Scher H.I. Sidlow R. Becker A.S. Wibmer A.G.

Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: a systematic review and meta-analysis of randomized controlled trials.

European urology oncology. 2: 605-616Smith R.A. Andrews K.S. Brooks D. Fedewa S.A. Manassaram‐Baptiste D. Saslow D. Wender R.C.

Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening.

CA: a cancer journal for clinicians. 69: 184-210Krishnamurthy N. Spencer E. Torkamani A. Nicholson L.

Liquid biopsies for cancer: coming to a patient near you.

Journal of clinical medicine. 6: 3Brönimann S. Pradere B. Karakiewicz P. Abufaraj M. Briganti A. Shariat S.F.

An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer.

Expert Review of Molecular Diagnostics. 20: 841-850Carlsson S.V. Roobol M.J.

Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.

Current opinion in urology. 27: 198

Biomarkers for prostate biopsy and risk stratification of patients with newly diagnosed prostate cancer.

Urology practice. 4: 315-321Kiebish M.A. Cullen J. Mishra P. Ali A. Milliman E. Rodrigues L.O. Chen E.Y. Tolstikov V. Zhang L. Panagopoulos K.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.

Journal of translational medicine. 18: 1-10

Whom to biopsy: prediagnostic risk stratification with biomarkers, nomograms, and risk calculators.

Urologic Clinics. 44: 517-524Mao Z. Ji A. Yang K. He W. Hu Y. Zhang Q. Zhang D. Xie L.

Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.

Medicine. 97Darson M.F. Pacelli A. Roche P. Rittenhouse H.G. Wolfert R.L. Young C.Y. Klee G.G. Tindall D.J. Bostwick D.G.

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.

Urology. 49: 857-862

Bosland M: Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231: Prostate 2003; 54 (4): 249–257. Urologic Oncology: Seminars and Original Investigations: Elsevier, 2003. pp. 414-415.

Denmeade S.R. Sokoll L.J. Dalrymple S. Rosen D.M. Gady A.M. Bruzek D. Ricklis R.M. Isaacs J.T.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

The Prostate. 54: 249-257

McGarty TP: Prostate Cancer Prognostic Tests: Pre and Post Diagnosis. Hal, 2015.

Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.

Nature Reviews Cancer. 17: 199-204

Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Va¨a¨na¨nen R-M, Pettersson K, Chun FK: Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clinical chemistry 2009, 55:765-773.

Yu R, d'Aquin M, Gasevic D, Kimmerle J, Herder E, Ewerth R: Lile2019: 8th international workshop on learning and education with web data. Companion Publication of the 10th ACM Conference on Web Science, 2019. pp. 15-16.

Inflammation, a key event in cancer development.

Molecular cancer research. 4: 221-233Erre G.L. Buscetta G. Mangoni A.A. Castagna F. Paliogiannis P. Oggiano M. Carru C. Passiu G. Zinellu A.

Diagnostic accuracy of different blood cells-derived indexes in rheumatoid arthritis: a cross-sectional study.

Medicine. 99McNally C.J. Ruddock M.W. Moore T. McKenna D.J.

Biomarkers that differentiate benign prostatic hyperplasia from prostate cancer: a literature review.

Cancer Management and Research. 12: 5225Coradduzza D. Cruciani S. Arru C. Garroni G. Pashchenko A. Jedea M. Zappavigna S. Caraglia M. Amler E. Carru C.

Role of miRNA-145, 148, and 185 and stem cells in prostate cancer.

International Journal of Molecular Sciences. 23: 1626Larne O. Hagman Z. Lilja H. Bjartell A. Edsjö A. Ceder Y.

miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis.

Carcinogenesis. 36: 858-866Avgeris M. Stravodimos K. Fragoulis E. Scorilas A.

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.

British journal of cancer. 108: 2573-2581

Feng F, Liu H, Chen A, Xia Q, Zhao Y, Jin X, Huang J: miR‐148‐3p and miR‐152‐3p synergistically regulate prostate cancer progression via repressing KLF4. Journal of cellular biochemistry 2019, 120:17228-17239.

Walter B.A. Valera V.A. Pinto P.A. Merino M.J.

Comprehensive microRNA profiling of prostate cancer.

Journal of Cancer. 4: 350Tian C. Deng Y. Jin Y. Shi S. Bi H.

Long non-coding RNA RNCR3 promotes prostate cancer progression through targeting miR-185-5p.

American journal of translational research. 10: 1562Ostadrahimi S. Valugerdi M.A. Hassan M. Haddad G. Fayaz S. Parvizhamidi M. Mahdian R. Esfahani P.F.

miR-1266-5p and miR-185-5p promote cell apoptosis in human prostate cancer cell lines.

Asian Pacific journal of cancer prevention: APJCP. 19: 2305

Tewari AK, Whelan P, Graham JD: Prostate cancer: diagnosis and clinical management: John Wiley & Sons, 2013.

Leone A. Gershman B. Rotker K. Butler C. Fantasia J. Miller A. Afiadata A. Amin A. Zhou A. Jiang Z.

Atypical small acinar proliferation (ASAP): is a repeat biopsy necessary ASAP? A multi-institutional review.

Prostate Cancer and Prostatic Diseases. 19: 68-71

High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate.

Modern Pathology. 31: 71-79McDonald A.C. Vira M. Shen J. Sanda M. Raman J.D. Liao J. Patil D. Taioli E.

Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.

The Prostate. 78: 411-418Ozen M. Karatas O.F. Gulluoglu S. Bayrak O.F. Sevli S. Guzel E. Ekici I.D. Caskurlu T. Solak M. Creighton C.J.

Overexpression of miR-145–5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression.

Cancer investigation. 33: 251-258

Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Rna. 14: 844-852Shen J. Wang Q. Gurvich I. Remotti H. Santella R.M.

Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma.

Hepatoma research. 2: 305Maioli M. Rinaldi S. Pigliaru G. Santaniello S. Basoli V. Castagna A. Fontani V. Ventura C.

REAC technology and hyaluron synthase 2, an interesting network to slow down stem cell senescence.

Scientific reports. 6: 1-8Harrell Jr., F.E. Lee K.L. Mark D.B.

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Statistics in medicine. 15: 361-387Harvey C. Pilcher J. Richenberg J. Patel U. Frauscher F.

Applications of transrectal ultrasound in prostate cancer.

The British journal of radiology. 85: S3-S17Sadeghi-Nejad H. Simmons M. Dakwar G. Dogra V.

Controversies in transrectal ultrasonography and prostate biopsy.

Ultrasound quarterly. 22: 169-175Chun F.K.-H. Steuber T. Erbersdobler A. Currlin E. Walz J. Schlomm T. Haese A. Heinzer H. McCormack M. Huland H.

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.

European urology. 49: 820-826Pernar C.H. Ebot E.M. Wilson K.M. Mucci L.A.

The epidemiology of prostate cancer.

Cold Spring Harbor perspectives in medicine. 8: a030361Merriel S.W. Funston G. Hamilton W.

Prostate cancer in primary care.

Advances in therapy. 35: 1285-1294Salido-Guadarrama A.I. Morales-Montor J.G. Rangel-Escareño C. Langley E. Peralta-Zaragoza O. Cruz Colin J.L. Rodriguez-Dorantes M.

Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.

Molecular medicine reports. 13: 4549-4560Naji L. Randhawa H. Sohani Z. Dennis B. Lautenbach D. Kavanagh O. Bawor M. Banfield L. Profetto J.

Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis.

The Annals of Family Medicine. 16: 149-154Smeenge M. Barentsz J. Cosgrove D. De La Rosette J. De Reijke T. Eggener S. Frauscher F. Kovacs G. Matin S.F. Mischi M.

Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel.

BJU international. 110: 942-948Scattoni V. Raber M. Abdollah F. Roscigno M. Dehò F. Angiolilli D. Maccagnano C. Gallina A. Capitanio U. Freschi M.

Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.

European urology. 57: 1-8Wolters T. van der Kwast T.H. Vissers C.J. Bangma C.H. Roobol M. Schröder F.H. van Leenders G.J.

False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.

The American journal of surgical pathology. 34: 35-43

High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.

Bosnian Journal of Basic Medical Sciences. 11: 223Balzano F. Campesi I. Cruciani S. Garroni G. Bellu E. Dei Giudici S. Angius A. Oggiano A. Rallo V. Capobianco G.

Epigenetics, stem cells, and autophagy: exploring a path involving miRNA.

International Journal of Molecular Sciences. 20: 5091Balzano F. Garroni G. Cruciani S. Bellu E. Dei Giudici S. Oggiano A. Capobianco G. Dessole S. Ventura C. Maioli M.

Behavioral changes in stem-cell potency by HepG2-exhausted medium.

Cells. 9: 1890Zhou X. Zhao F. Wang Z.-N. Song Y.-X. Chang H. Chiang Y. Xu H.-M.

Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation.

Oncology reports. 27: 447-454

Zhang J-g, Shi Y, Hong D-f, Song M, Huang D, Wang C-y, Zhao G: MiR-148b suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting WNT1/β-catenin pathway. Scientific reports 2015, 5:1-9.

Ostadrahimi S. Fayaz S. Parvizhamidi M. Abedi-Valugerdi M. Hassan M. Kadivar M. Teimoori-Toolabi L. Asgari M. Shahrokh H. Abolhasani M.

Downregulation of miR-1266-5P, miR-185-5P and miR-30c-2 in prostatic cancer tissue and cell lines.

Oncology letters. 15: 8157-8164Qu F. Cui X. Hong Y. Wang J. Li Y. Chen L. Liu Y. Gao Y. Xu D. Wang Q.

MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.

Molecular and cellular biochemistry. 377: 121-130

The roles of microRNAs in epigenetic regulation.

Current opinion in chemical biology. 51: 11-17Kelly B.D. Miller N. Sweeney K.J. Durkan G.C. Rogers E. Walsh K. Kerin M.J.

A circulating microRNA signature as a biomarker for prostate cancer in a high risk group.

Journal of clinical medicine. 4: 1369-1379Kosaka N. Iguchi H. Ochiya T.

Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis.

Cancer science. 101: 2087-2092

Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers.

Medicinal research reviews. 32: 326-348Wang H. Peng R. Wang J. Qin Z. Xue L.

Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.

Clinical epigenetics. 10: 1-10Farazi T.A. Hoell J.I. Morozov P. Tuschl T.

MicroRNAs in human cancer.

MicroRNA cancer regulation. : 1-20Condrat C.E. Thompson D.C. Barbu M.G. Bugnar O.L. Boboc A. Cretoiu D. Suciu N. Cretoiu S.M. Voinea S.C.

miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis.

Cells. 9: 276Leichter A.L. Sullivan M.J. Eccles M.R. Chatterjee A.

MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours.

Molecular cancer. 16: 1-17Tiberio P. Callari M. Angeloni V. Daidone M.G. Appierto V.

Challenges in using circulating miRNAs as cancer biomarkers.

BioMed research international. 2015

Attard G, Parker C, Eeles R: Schroff der F, Tomlins SA, Tannock I, Drake CG, de Bono JS. 2016. Prostate cancer The Lancet, 387:70-82.

Hussain M. Goldman B. Tangen C. Higano C.S. Petrylak D.P. Wilding G. Akdas A.M. Small E.J. Donnelly B.J. Sundram S.K.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Journal of clinical oncology. 27: 2450Hayashi T. Fujita K. Tanigawa G. Kawashima A. Nagahara A. Ujike T. Uemura M. Takao T. Yamaguchi S. Nonomura N.

Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer.

Oncotarget. 835255Bahig H. Taussky D. Delouya G. Nadiri A. Gagnon-Jacques A. Bodson-Clermont P. Soulieres D.

Neutrophil count is associated with survival in localized prostate cancer.

BMC cancer. 15: 1-8Lin Y.-T. Lee M.T.-S. Huang Y.-C. Liu C.-K. Li Y.-T. Chen M.

Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index–reinforced machine learning model.

Open Medicine. 14: 593-606Rhoden E. Telöken C. Sogari P. Vargas Souto C.

The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction.

International journal of impotence research. 14: 245-250

Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ, Ding QN: The potential of microRNAs as human prostate cancer biomarkers: a meta‐analysis of related studies. Journal of cellular biochemistry 2018, 119:2763-2786.

Watahiki A. Wang Y. Morris J. Dennis K. O'Dwyer H.M. Gleave M. Gout P.W. Wang Y.

MicroRNAs associated with metastatic prostate cancer.

PloS one. 6e24950

Cui SY, Wang R, Chen LB: Micro RNA‐145: a potent tumour suppressor that regulates multiple cellular pathways. Journal of cellular and molecular medicine 2014, 18:1913-1926.

Jackson B.L. Grabowska A. Ratan H.L.

MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers.

BMC cancer. 14: 1-10Andl T. Ganapathy K. Bossan A. Chakrabarti R.

MicroRNAs as guardians of the prostate: those who stand before cancer. What do we really know about the role of microRNAs in prostate biology?.

International Journal of Molecular Sciences. 21: 4796Li Y. Deng X. Zeng X. Peng X.

The role of Mir-148a in cancer.

Journal of cancer. 7: 1233Coppola V. De Maria R. Bonci D.

MicroRNAs and prostate cancer.

Endocrine-related cancer. 17: F1Kristensen H. Thomsen A.R. Haldrup C. Dyrskjøt L. Høyer S. Borre M. Mouritzen P. Ørntoft T.F. Sørensen K.D.

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.

Oncotarget. 730760Luu H.N. Lin H.-Y. Sørensen K.D. Ogunwobi O.O. Kumar N. Chornokur G. Phelan C. Jones D. Kidd L. Batra J.

miRNAs associated with prostate cancer risk and progression.

BMC urology. 17: 1-18